Last reviewed · How we verify
The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours. (LUMEN)
The purpose of this study is to determine if 68Gallium-octreotate and 18Fluorodesoxyglucose uptake, apparent diffusion coefficient and post 177Lu-octreotate SPECT/CT dosimetry are reliable predictors for lesion-by-lesion treatment outcome.
Details
| Lead sponsor | Jules Bordet Institute |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 37 |
| Start date | 2013-05 |
| Completion | 2022-09-19 |
Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
Interventions
- Intravenous injection of 177Lu-octreotate
Primary outcomes
- The time to progression (TTP) for each target lesion assessed on MRI (or on CT scan if MRI is not possible). — 4 years [Anticipated]
TTP is defined as the time between treatment initiation and objective tumor progression with censoring of patients who die as a result of any cause.
Countries
Belgium